MDA

What is MDA?

MDA, or 3,4-methylenedioxyamphetamine, is a synthetic ring-substituted amphetamine with stimulant, empathogenic and psychedelic properties. It is also known by the informal names Sass, Sally and Love. MDA is closely related to MDMA, but it lacks the additional N-methyl group that distinguishes MDMA from its parent compound. MDA is also formed as a minor active metabolite when the body processes MDMA, although it can be taken as a substance in its own right.

History and chemical structure

MDA was first synthesized in 1910, before MDMA, and was later investigated for several possible medical uses, including as an appetite suppressant and a tranquillizing agent. It was never established as a widely used medicine. Its nonmedical use became more visible in the second half of the twentieth century, often under names that overlapped with those used for MDMA.

The molecule contains a methylenedioxy ring substituent at the 3- and 4-positions of the aromatic ring, together with the alpha-methyl group characteristic of amphetamines. The terminal nitrogen is primary, whereas MDMA carries an N-methyl substituent. This difference influences transporter interactions, metabolism and the balance between stimulant and psychedelic-like effects.

Pharmacology

MDA acts as a substrate at monoamine transporters and promotes the release of serotonin, noradrenaline and dopamine. Compared with MDMA, its pharmacological profile is somewhat more dopaminergic and it has stronger agonist activity at the 5-HT2A receptor. This helps explain why MDA is often described as having a more pronounced perceptual component than MDMA, while retaining empathogenic and stimulant effects.

Transporter-mediated release and direct receptor activation contribute differently to the effects. The release of monoamines contributes to stimulation, mood elevation and social-emotional effects, while 5-HT2A activity can contribute to visual and other psychedelic-like changes. Neither mechanism alone accounts for the complete experience.

Human pharmacology and reported effects

For many years, modern human research on MDA was sparse. A 2019 controlled study in healthy volunteers found that MDA produced both MDMA-like emotional effects and more pronounced psychedelic-like changes, with subjective effects lasting longer than those reported in the investigators’ earlier MDMA study. In a randomized, double-blind, placebo-controlled crossover trial published online in September 2025, Straumann and colleagues directly compared MDA and MDMA in the same 23 healthy adults. MDA produced stronger and longer-lasting subjective effects, greater stimulation, more visual alterations and higher ratings of fear and unpleasant effects than MDMA. The average duration of the main subjective effects was about six hours for MDA and four hours for MDMA in that study. The findings are reported in the 2025 controlled comparison of MDA and MDMA in healthy participants.

These results do not mean that every person experiences MDA as more psychedelic or more difficult than MDMA. The study used screened volunteers under controlled conditions, and its findings describe the tested formulation and setting. They do, however, provide direct evidence that the two closely related compounds are not interchangeable in their acute effects.

Physical and perceptual effectsCognitive and emotional effects
  • Stimulation: increased energy, wakefulness and physical activation are reported.
  • Autonomic effects: increased heart rate, blood pressure, sweating and pupil dilation can occur.
  • Visual changes: colour enhancement, visual distortions and more complex imagery are reported more often than with MDMA.
  • Bodily sensations: tactile enhancement, jaw tension and muscle tightness may occur.
  • Physical discomfort: nausea, overheating and restlessness are possible.
  • Empathy and closeness: feelings of trust, emotional openness and social connection are described.
  • Euphoria: mood elevation and a sense of well-being may occur.
  • Perceptual changes: altered visual processing and unusual associations in thought can give the experience a more psychedelic character.
  • Fear and distress: controlled research found higher ratings of fear and unpleasant effects than with MDMA.
  • After-effects: fatigue, reduced appetite, headache and low energy may persist after the acute effects have subsided.

Metabolism and toxicology

MDA is metabolized through O-demethylenation, hydroxylation and conjugation pathways. It is also produced from MDMA through N-demethylation, so the detection of MDA in a biological sample does not by itself prove that MDA was taken directly. The relative concentrations of parent compounds and metabolites, together with other markers, are needed for interpretation.

Acute toxicity can involve cardiovascular strain, hyperthermia, agitation and disturbances of fluid balance. A review of the role of MDA and MDMA metabolism in toxicity discusses reactive metabolites and their possible contribution to serotonergic neurotoxicity. Much of this evidence comes from experimental models, and translating it into long-term human outcomes is not straightforward. The risks are not limited to the parent molecule: reactive metabolites and environmental factors, including heat and prolonged exertion, can influence the severity of intoxication.

The 2025 human comparison found a less favourable acute tolerability profile for MDA than for MDMA under the conditions tested. It does not establish a universal risk ranking, but it reinforces the importance of treating the two substances as distinct compounds rather than assuming that their shared chemical family guarantees similar effects.

MDA Products

MDA crystals

MDA crystals

Price range: $473.00 through $9,135.00
Select options
MDA powder

MDA powder

Price range: $473.00 through $9,135.00
Select options
MDA pills

MDA pills

Price range: $315.00 through $1,050.00
Select options

Scientific Data

Identity and Structure

Chemical Name3,4-Methylenedioxyamphetamine (MDA)
Catalog Entity TypeCompound
FormulaC10H13NO2
Molar Mass179.219 g·mol−1
CAS4764-17-4
CAS Numbers and Substance Forms4764-17-4
SynonymsMDA; Tenamfetamine; Amphedoxamine; Sally; Sassafras; Sass-a-frass; Sass; Mellow Drug of America; Hug drug; Love; 3,4-Methylenedioxy-α-methylphenethylamine; 5-(2-Aminopropyl)-1,3-benzodioxole; EA-1298; NSC-9978; NSC-27106; SKF-5
IUPAC Name1-(2H-1,3-Benzodioxol-5-yl)propan-2-amine
InChIInChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3
InChIKeyNGBBVGZWCFBOGO-UHFFFAOYSA-N
SMILESNC(C)CC1=CC2=C(C=C1)OCO2

Chemical Identifiers

PubChem CID1614
ChemSpider ID1555
DrugBank IDDB01509
ChEBI IDCHEBI:166520
KEGG IDD12715
UNIIXJZ28FJ27W
ChEMBL IDChEMBL6731
CompTox DTXSIDDTXSID40859958
ECHA ID100.230.706

Clinical Data

Drug ClassSerotonin–norepinephrine–dopamine releasing agent; Serotonin 5-HT2 receptor agonist; Entactogen; Empathogen; Serotonergic psychedelic; Hallucinogen; Stimulant
Routes of AdministrationOral, sublingual, insufflation, intravenous
ATC CodeNone

Pharmacokinetics

MetabolismHepatic (CYP extensively involved)
Onset of Action0.7 hours (range 0.3 to 1.1 hours)
Peak: 2.0 hours (range 1.0–3.5 hours)
Elimination Half-life8.4–10.9 hours
Duration of Action5–8 hours (range 1–10 hours)
ExcretionRenal

Legal Status

Legal Status (Wikipedia Source Text)AU: S9 (Prohibited substance)
BR: Class F2 (Prohibited psychotropics)
CA: Schedule I
DE: Anlage I (Authorized scientific use only)
UK: Class A
US: Schedule I
UN: Psychotropic Schedule I
EU: Fully prohibited
SE: Förteckning I

Sources and Attribution

Wikipedia Source URLhttps://en.wikipedia.org/?curid=692929